BrainStorm Cell Therapeutics has had a number of recent exciting announcements, including the news that their Phase I/II clinical trial studying stem cell technology for the treatment of ALS is being fast tracked to a Phase IIa. On the heels of these developments, BrainStorm Cell Therapeutics announced they have appointed well known biotech executive Alon Natanson as their new Chief Executive Officer. Before joining BrainStorm, Natanson served as the Director of Marketing and Finance for Teva Pharmaceuticals Industries Ltd. in the Copaxone division where he helped to commercialize patented therapeutics for multiple sclerosis. Natanson replaces Dr. Adrian Harel who held the position since February 2011 and is transitioning to a scientific role within BrainStorm.
Click here to read more.Share this: